Literature DB >> 24322908

Impact of hypoalphalipoproteinemia on quality of life in Taiwanese women with central obesity.

I-Ju Chen1, Wei-Chun Lin, Chia-Yu Liu, You-Lung Song, Jung-Peng Chiu, Chung-Hua Hsu.   

Abstract

PURPOSE: To investigate the relationship between health-related quality of life (HRQoL) and different cutoff value of low level of high-density lipoprotein cholesterol (HDL-C) in Taiwanese women with different definition of obesity.
METHODS: Prospective observational study in women with central obesity was conducted in Taipei City Hospital. A total of 572 women were screened at our clinic, and 227 of them with a body mass index ≧27 kg/m2 defined by the Department of Health in Taiwan and weight circumference ≧80 cm were eligible for the study. We defined two groups as group A-low HDL (HDL-C < 40 mg/dL) and group B-high HDL (HDL-C < 50 mg/dL) according to different definition of hypoalphalipoproteinemia in obese women.
RESULTS: Significantly reduced HRQoL score was noted in group A-low HDL compared to group A-high HDL (HDL-C ≧ 40 mg/dL), but not between group B-low HDL and group B-high HDL (HDL-C ≧ 50 mg/dL). Positively correlation was noted between HDL-C level and physical domain of HRQoL score. HDL-C contributes independently to physical domain of HRQoL score after controlling for other factors. Decreased leptin and adiponectin level were noted in hypoalphalipoproteinemia groups.
CONCLUSION: Taiwanese obese women with hypoalphalipoproteinemia have adverse impact on HRQoL, especially when the HDL-C level is lower than 40 mg/dL. Both hypoalphalipoproteinemia and hypertension accounted for a great variance to lower scores of physical domain of HRQoL with positively correlation with HDL-C level observed. Decreased leptin and adiponectin were also observed in hypoalphalipoproteinemia group, which implied increased cardiovascular risk. HDL-C level may deem as another indicator for HRQoL in women with central obesity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24322908     DOI: 10.1007/s11136-013-0601-8

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  30 in total

1.  The metabolic syndrome.

Authors:  James B Meigs
Journal:  BMJ       Date:  2003-07-12

2.  Leptin and HDL-cholesterol in non-diabetic normotensive subjects.

Authors:  G M Marinari; N Scopinaro; G F Adami
Journal:  Obes Surg       Date:  2001-06       Impact factor: 4.129

3.  The disease burden associated with overweight and obesity.

Authors:  A Must; J Spadano; E H Coakley; A E Field; G Colditz; W H Dietz
Journal:  JAMA       Date:  1999-10-27       Impact factor: 56.272

4.  Health-related quality of life in metabolic syndrome: The Korea National Health and Nutrition Examination Survey 2005.

Authors:  Sang Shin Park; Yeong Sook Yoon; Sang Woo Oh
Journal:  Diabetes Res Clin Pract       Date:  2010-12-04       Impact factor: 5.602

5.  Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease. Results from the Québec cardiovascular study.

Authors:  B Lamarche; J P Després; S Moorjani; B Cantin; G R Dagenais; P J Lupien
Journal:  Atherosclerosis       Date:  1996-01-26       Impact factor: 5.162

6.  Metabolic syndrome and health-related quality of life among U.S. adults.

Authors:  Earl S Ford; Chaoyang Li
Journal:  Ann Epidemiol       Date:  2008-03       Impact factor: 3.797

Review 7.  Low high-density lipoprotein cholesterol: current status and future strategies for management.

Authors:  Vibhuti Singh; Rakesh Sharma; Ajoy Kumar; Prakash Deedwania
Journal:  Vasc Health Risk Manag       Date:  2010-10-29

8.  Serum adiponectin is associated with high-density lipoprotein cholesterol, triglycerides, and low-density lipoprotein particle size in young healthy men.

Authors:  Tsutomu Kazumi; Akira Kawaguchi; Tsutomu Hirano; Gen Yoshino
Journal:  Metabolism       Date:  2004-05       Impact factor: 8.694

9.  Decreased plasma adiponectin concentrations in women with dyslipidemia.

Authors:  Miyao Matsubara; Shoji Maruoka; Shinji Katayose
Journal:  J Clin Endocrinol Metab       Date:  2002-06       Impact factor: 5.958

Review 10.  Quality of life and obesity.

Authors:  R L Kolotkin; K Meter; G R Williams
Journal:  Obes Rev       Date:  2001-11       Impact factor: 9.213

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.